RESUMO
Dengue fever is a virus spread by mosquitoes that has no effective treatment or vaccination. Several dengue cases combined with the current COVID-19 pandemic, exacerbates this problem. Two proteins, NS5 methyltransferase and NS2B/NS3 primary protease complexes, are crucial for dengue viral replication and are the target sites for antiviral development. Thus, this study screened published literature and identified 162 marine fungus-derived compounds with active bioavailability. Following Lipinski's rules and antiviral property prediction, 41 compounds were selected for docking with NS5 methyltransferase and NS2B/NS3 protease (PDB ID: 6IZZ and 2FOM) to evaluate compounds that could stop the action of dengue viral protein complexes. To find the best candidates, computational ADME, toxicity, and drug target prediction were performed to estimate the potential of the multi-targeting fungal-derived natural compounds. Analyzing the result from 41 compounds, Chevalone E (-13.5 kcal/mol), Sterolic acid (-10.3 kcal/mol) showed higher binding energy against dengue NS2B/NS3 protease; meanwhile, Chevalone E (-12.0 kcal/mol), Brevione K (-7.4 kcal/mol), had greater binding affinity against NS5 methyltransferase. Consequently, this study suggests that Chevalone E is an effective inhibitor of NS5 methyltransferase and NS2B/NS3 protease. Ligand-based virtual screening from DrugBank was utilized to predict biologically active small compounds against dengue virus NS2B/NS3 major protease and NS5 methyltransferase. Both licensed medications, estramustine (DB01196) and quinestrol (DB04575), were found to be similar to Chevalone E, with prediction scores of 0.818 and 0.856, respectively. In addition, cholic acid (DB02659), acitretin (DB00459), and mupirocin (DB00410) are similar to Sterolic acid, zidovudine (DB00495), imipenem (DB01598), and nadolol (DB01203) are similar to Brocazine A, and budesonide (DB01222) and colchicine (DB01394) are related to Brevione K. These findings suggest that these could be feasible dengue virus treatment options, meaning that more research is needed.
RESUMO
Objectives: The purpose of this research was to look into the impacts after the implication of feeding broiler chickens with spirulina in arsenic-incited toxicities. Materials and Methods: Birds (n = 125) were distributed equally (n = 25) into four groups treated (T 1, T 2, T 3, T 4) and a group controlled, T 0 (normal feed and water without supplement), the group taking in arsenic trioxide (100 mg/l)-induced diet (T 1), and the groups T 2, T 3, and T 4 (feed supplemented with 50, 100, and 200 mg/l of spirulina along with Arsenic Trioxide, respectively). The body weight and hematobiochemical parameters were recorded every 7 days. Results: Different growth development indicators, e.g., body weight, feed intake ratio, feed conversion ratio, depression, and skin lesions, were weak in arsenic trioxide groups and upstanding in the arsenic plus spirulina group. Over and above, the lack of body weight gain in chicken (2.7%-13.00%) in the arsenic-introduced groups given spirulina (T 2, T 3, and T 4) overtook the mere groups exposed to arsenic, where the lack of weight gain was optimum (54.90%). Thereafter, in arsenic-instituted groups given spirulina (T 2, T 3, and T 4), the drop in total erythrocyte count, total leukocyte count, hemoglobin, and packed cell volume values became less notable than in arsenic pollutant groups (T 1, p < 0.01). Two measurable factors (serum glutamate pyruvate transaminase and serum glutamic oxaloacetic transaminase) were substantially (p < 0.01) raised in the group (T 1) treated with arsenic, but in the arsenic-induced groups (T 2, T 3, and T 4) treated with spirulina, they were elevated less. Conclusion: This study demonstrates that arsenic is a threat to poultry. However, spirulina may be advantageous for alleviating the effects of arsenic in poultry.